GSK PLC

ISIN: GB00BN7SWP63 WKN: BN7SWP6 Asset Class: Stock



Fax: +

79 New Oxford Street Web: http://www.gsk.com

WC1A 1DG London E-mail: -

Company Profile

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

11.2023

02.2024

05.2024

08.2024

Financial figures, Fiscal year: from 01.01. to 31.12.

| | 20: | 2023 | | 2022 | | 2021 | |
|--------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|--|
| Financial figures | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity | |
| Current assets | 18,644,000,000 | | 20,769,000,000 | | 18,674,000,000 | | |
| Common stock capital | | 1,348,000,000 | | 1,347,000,000 | | 1,347,000,000 | |
| Fixed assets | 40,361,000,000 | | 39,377,000,000 | | 60,429,000,000 | | |
| Equity capital of a company | | 12,795,000,000 | | 10,096,000,000 | | 21,342,000,000 | |
| Cash and cash equivalents | 2,936,000,000 | | 3,723,000,000 | | 4,274,000,000 | | |
| Accrued liabilities | | 2,835,000,000 | | 3,111,000,000 | | 3,743,000,000 | |
| Other assets | - | | - | | - | | |
| Current liabilities | | 21,068,000,000 | | 22,810,000,000 | | 23,670,000,000 | |
| Prepayments and accrued income | - | | - | | - | | |
| Non-current liabilities | | 25,142,000,000 | | 27,240,000,000 | | 34,091,000,000 | |
| Different income | | - | | - | | - | |
| Other liabilities | | 6,791,000,000 | | 6,805,000,000 | | 6,220,000,000 | |
| Total assets | 59,005,000,000 | 59,005,000,000 | 60,146,000,000 | 60,146,000,000 | 79,103,000,000 | 79,103,000,000 | |

Balance notes

| | 2023 | 2022 | 2021 |
|---------------------|---------|---------|---------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 70,212 | 69,400 | 90,096 |
| Equity ratio | 20.75% | 15.95% | 34.93% |
| Debt-equity ratio | 381.95% | 526.91% | 186.30% |

Others

| | 2023 | 2022 | 2021 |
|------------------|--------|--------|-------|
| Tax Expense Rate | 12.46% | 12.56% | 6.40% |

GSK PLC

ISIN: GB00BN7SWP63 WKN: BN7SWP6 Asset Class: Stock

| Income statement | | | |
|--|----------------|----------------|----------------|
| | 2023 | 2022 | 2021 |
| Turnover | 30,328,000,000 | 29,324,000,000 | 34,114,000,000 |
| Net income | 4,928,000,000 | 4,461,000,000 | 4,385,000,000 |
| EBIT | 8,122,359,600 | 7,678,495,200 | 7,371,020,400 |
| Operating income before taxes | 6,069,000,000 | 5,630,000,000 | 5,409,000,000 |
| Cash Flow | 6,348,000,000 | 6,625,000,000 | 7,202,000,000 |
| Net interest income | -720,000,000 | -788,000,000 | -752,000,000 |
| Research and development expenses | 5,245,000,000 | 4,836,000,000 | 4,635,000,000 |
| Income taxes | 756,000,000 | 707,000,000 | 346,000,000 |
| Result from investments in subsidaries, associates and other | -5,000,000 | -2,000,000 | 33,000,000 |
| Revenues per employee | 516,784 | 505,522 | 453,006 |

| Board of Directors | | |
|---------------------------|-------------------------------|--|
| | | |
| Jonathan Symonds | Chairman of Supervisory Board | |
| Anne Beal | Member of Supervisory Board | |
| Hal Barron | Member of Supervisory Board | |
| Harry Dietz | Member of Supervisory Board | |
| Jeannie Lee | Member of Supervisory Board | |
| Jesse Goodman | Member of Supervisory Board | |
| Vishal Sikka | Member of Supervisory Board | |
| Charles Bancroft | Member of Supervisory Board | |
| Elizabeth Anderson | Member of Supervisory Board | |
| Julie Brown | Member of Supervisory Board | |
| Wendy Becker | Member of Supervisory Board | |

| Members of Management | t Board |
|----------------------------------|-------------------------------|
| Emma Walmsley | Chairman of Managing Board |
| Anne-Marie Martin | Member of Executive Committee |
| Carlo Russo | Member of Executive Committee |
| Christopher Corsico | Member of Executive Committee |
| Tony Wood | Member of Executive Committee |
| Amy Altshul | Member of Executive Committee |
| Anita Kidgell | Member of Executive Committee |
| Claire Lund | Member of Executive Committee |
| David Redfern | Member of Executive Committee |
| Diana Conrad | Member of Executive Committee |
| Frannie DeFranco | Member of Executive Committee |
| Graham Rivers | Member of Executive Committee |
| James Ford | Member of Executive Committee |
| Luke Miels | Member of Executive Committee |
| María Cristina de Luna Basagoiti | Member of Executive Committee |
| Maya Martinez-Davis | Member of Executive Committee |
| Michael Elmore | Member of Executive Committee |
| Mick Readey | Member of Executive Committee |
| Philip Thomson | Member of Executive Committee |
| Regis Jean-Pierre Simard | Member of Executive Committee |
| Shobie Ramakrishnan | Member of Executive Committee |
| Sonya Ghobrial | Member of Executive Committee |
| Timothy Woodthorpe | Member of Executive Committee |
| Victoria Whyte | Member of Executive Committee |
| | |